Aclidinium: In chronic obstructive pulmonary disease

Drugs

Volumn 72, Issue 15, 2012, Pages 1999-2011

  Frampton, James E ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Aclidinium bromide; Adis Drug Profiles; Chronic obstructive pulmonary disease

Indexed keywords

ACLIDINIUM BROMIDE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRETARIS; BRONCHODILATING AGENT; EKLIRA; FORMOTEROL; GENUAIR; GLYCOPYRRONIUM BROMIDE; LONG ACTING DRUG; MUSCARINIC RECEPTOR BLOCKING AGENT; PRESSAIR; SALMETEROL; SHORT ACTING DRUG; TIOTROPIUM BROMIDE; TUDORZA; UMECLIDINIUM; UNCLASSIFIED DRUG;

ANTICHOLINERGIC EFFECT; ARTICLE; BACKACHE; BRONCHITIS; BRONCHODILATATION; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); CONSTIPATION; COUGHING; DIARRHEA; DISEASE EXACERBATION; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EYE DISEASE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL DISEASE; HEADACHE; HEALTH STATUS; HEART DISEASE; HEART INFARCTION; HUMAN; HYPERTENSION; KIDNEY DISEASE; LONG TERM CARE; MAINTENANCE THERAPY; MAXIMUM PLASMA CONCENTRATION; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; POWDER INHALER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; SIDE EFFECT; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; URINARY TRACT DISEASE; XEROSTOMIA;

BIOLOGICAL AVAILABILITY; BRONCHODILATOR AGENTS; DYSPNEA; HUMANS; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TROPANES;

EID: 84867287162     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11209700-000000000-00000     Document Type: Article

References (52)

1. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007 Sep 15; 176 (6): 532-55 (Pubitemid 47403272)
2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (revised 2011) [online]. Available from URL: http://www.goldcopd. org/uploads/users/files/GOLD-Report-2011-Feb21.pdf [Accessed 2012 Jun 14]
3. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007 Sep 1; 370 (9589): 765-73 (Pubitemid 47321908)
4. Barnes PJ. New therapies for chronic obstructive pulmonary disease. Med Princ Pract 2010 Jul; 19 (5): 330-8
5. Cazzola M, Matera MG. Emerging inhaled bronchodilators: an update. Eur Respir J 2009 Sep; 34 (3): 757-69
6. Cazzola M, Page CP, Calzetta L, et al. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev 2012 Jul; 64 (3): 450-504
7. Jones PW, Rennard SI, Agusti A, et al. Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Respir Res 2011; 12: 55
8. Joos GF, Schelfhout VJ, Pauwels RA, et al. Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients. Respir Med 2010 Jun; 104 (6): 865-72
9. Jansat JM, Lamarca R, Garcia Gil E, et al. Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects. Int J Clin Pharmacol Ther 2009 Jul; 47 (7): 460-8
10. Chrystyn H, Niederlaender C. The Genuair-inhaler: a novel, multidose dry powder inhaler. Int J Clin Pract 2012 Mar; 66 (3): 309-17
11. Gavalda A, Miralpeix M, Ramos I, et al. Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile. J Pharmacol Exp Ther 2009 Nov; 331 (2): 740-51
12. Lieberman JA 3rd. Managing anticholinergic side effects. Prim Care Companion J Clin Psychiatry 2004; 6 Suppl. 2: 20-3
13. Lee TA, Pickard AS, AuDH, et al. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med 2008; 149: 380-90
14. Milara J, Serrano A, Peiro T, et al. Aclidinium inhibits human lung fibroblast to myofibroblast transition. Thorax 2012 Mar; 67 (3): 229-37
15. Cortijo J, Mata M, Milara J, et al. Aclidinium inhibits cholinergic and tobacco smoke-induced MUC5AC in human airways. Eur Respir J 2011 01 Feb; 37 (2): 244-54
16. Cortijo J, Milara J, Peiro T, et al. Cigarette smoke-induced fibroblast activation is attenuated by aclidinium in vitro [abstract]. Am J Respir Crit Care Med 183; 2011: A3596 [online]. Available from URL: http://ajrccm. atsjournals. org/cgi/reprint/183/1-MeetingAbstracts/A3596 [Accessed 2012 Jun 18]
17. Dominguez-Fandos D, Puig-Pey R, Ferrer E, et al. Effects of aclidinium bromide on airway remodeling in guinea pigs exposed to cigarette smoke for 6 months [abstract]. Am J Respir Crit Care Med 183; 2011: A3595 [online]. Available from URL: http://ajrccm.atsjournals.org/cgi/reprint/183/1- MeetingAbstracts/A3595 [Accessed 2012 Jun 18]
18. Singh D, Magnussen H, Kirsten A, et al. A randomized, placebo-and active-controlled dose finding study of aclidinium bromide administered twice a day in COPD patients. Pulm Pharmacol Ther 2012 Jun; 25 (3): 248-53
19. Chanez P, Burge PS, Dahl R, et al. Aclidinium bromide provides long-acting bronchodilation in patients with COPD. Pulm Pharmacol Ther 2010 Feb; 23 (1): 15-21
20. Vestbo J, Vogelmeier C, Creemers J, et al. Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD. COPD 2010 Sep; 7 (5): 331-6
21. Fuhr R, Magnussen H, Sarem K, et al. Efficacy of aclidinium bromide 400 mg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD. Chest 2012 Mar; 141 (3): 745-52
22. Donohue JF. Minimal clinically important differences in COPD lung function. COPD 2005 Mar; 2 (1): 111-24 (Pubitemid 40776231)
23. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008 Feb; 31 (2): 416-69
24. Maltais F, Celli B, Casaburi R, et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respir Med 2011 Apr; 105 (4): 580-7
25. Lasseter KC, Aubets J, Chuecos F, et al. Aclidiniumbromide, a long-acting antimuscarinic, does not affect QT interval in healthy subjects. J Clin Pharmacol 2011 Jun; 51 (6): 923-32
26. Almirall, S.A. Eklira Genuair 322 micrograms inhalation powder: summary of product characteristics. [online]. Available from URL: http://ec.europa.eu/ health/documents/community-register/2012/20120720123594/anx-123594-en. pdf [Accessed 2012 Aug 23]
27. Forest Pharmaceuticals, Inc. Tudorza Pressair (aclidinium bromide inhalation powder): US precribing information [online]. Available from URL: http://www.frx.com/pi/tu dorza pi.pdf [Accessed 2012 Aug 23]
28. Jansat JM, Lamarca R, De Miquel G, et al. Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants. J Clin Pharmacol 2009 Oct; 49 (10): 1239-46
29. Lasseter K, Dilzer S, Jansat JM, et al. Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers. Pulm Pharmacol Ther 2012 Apr; 25 (2): 193-9
30. Ortiz S, Flach S, Caracta C, et al. Safety and tolerability of aclidinium administered intravenously and absolute bioavailability of inhaled aclidinium in healthy male participants. J Clin Pharmacol 2012 Jun; 52 (6): 819-27
31. Ortiz S, Flach S, Ho J, et al. Mass balance and metabolism of aclidinium bromide following intravenous administration of [14C]-aclidinium bromide in healthy subjects. Biopharm Drug Dispos 2012 Jan; 33 (1): 39-45
32. Newman SP, Sutton DJ, Segarra R, et al. Lung deposition of aclidinium bromide from Genuair , a multidose dry powder inhaler. Respiration 2009; 78 (3): 322-8
33. de la Motte S, Beier J, Schmid K, et al. Pharmacokinetics and safety of aclidinium bromide in younger and elderly patients with chronic obstructive pulmonary disease. Int J Clin Pharm Ther 2012 May 22; 50 (6): 403-12
34. Schmid K, Pascual S, Gil EG, et al. Pharmacokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: a phase I, open-label, single-dose clinical trial. Clin Ther 2010 Sep; 32 (10): 1798-812
35. US Food and Drug Administration. Pulmonary Allergy Drugs Advisory Committee Meeting, February 23, 2012. NDA 202-450: aclidinium bromide for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including bronchitis and emphysema [online]. Available from URL: http://www.fda.gov/downloads/AdvisoryCommittees/ Com mitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugs AdvisoryCommittee/ UCM292620.pdf [Accessed 2012 Aug 23]
36. Prat M, Fernandez D, Buil MA, et al. Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: identification of (3R)-3-{[hydroxy (di-2-thienyl)acetyl] oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[ 2.2.2]octane bromide (aclidinium bromide). J Med Chem 2009 Aug 27; 52 (16): 5076-92
37. Sentellas S, Ramos I, Alberti J, et al. Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites. Eur J Pharm Sci 2010 Mar 18; 39 (5): 283-90
38. Alberti J, Martinet A, Sentellas S, et al. Identification of the human enzymes responsible for the enzymatic hydrolysis of aclidinium bromide. Drug Metab Dispos 2010 Jul; 38 (7): 1202-10
39. Alberti JJ, Sentellas S, Salva M. In vitro liver metabolism of aclidinium bromide in preclinical animal species and humans: identification of the human enzymes involved in its oxidative metabolism. Biochem Pharmacol 2011 Mar 15; 81 (6): 761-76
40. Kerwin EM, D'Urzo AD, Gelb AF, et al. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD 2012 Apr; 9 (2): 90-101
41. Jones PW, Singh D, Bateman ED, et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J. Epub 2012 Mar 22
42. Jones P, Agusti A, Bateman E, et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: improvement in symptoms and health status in the ATTAIN study [abstract]. Chest 2011; 140 (4-MeetingAbstracts): 547A [online]. Available from URL: http://journal.publica tions.chestnet.org/article. aspx?articleid=1046335 [Accessed 2012 Jun 18]
43. Jones P, Singh D, Agusti A, et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): reduction in exacerbations as defined by healthcare utilization and the EXACT diary card [abstract]. Chest 2011; 140 (4-MeetingAbstracts): 529A [online]. Available from URL: http://journal.publications.chestnet. org/article.aspx?articleid=1045694 [Accessed 2012 Jun 18]
44. Forest Research Institute, Inc. Aclidinium bromide in chronic obstructive pulmonary disease NDA 202450. FDA advisory briefing document [online]. Available from URL: http://www.fda.gov/downloads/AdvisoryCommittees/Com mitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugs AdvisoryCommittee/ UCM292624.pdf [Accessed 2012 Jun 6]
45. Data on file, Forest Research Institute, 2012
46. Gelb AF, Make BJ, Tashkin DP, et al. Long-term efficacy and safety of twice-daily aclidinium bromide in COPD patients: a one-year study [abstract]. Am J Respir Crit Care Med 185; 2012: A2256 [online]. Available from URL: http://ajrccm.atsjournals.org/cgi/content/short/185/1-Meet ingAbstracts/A2256? rss=1 [Accessed 2012 Jun 18]
47. D'Urzo AD, Kerwin EM, Donohue JF, et al. Long-term extension study of ACCORD COPD I: effects of two doses of twice daily aclidinium bromide in COPD patients [abstract]. Am J Respir Crit Care Med 185; 2012: A2913 [online]. Available from URL: http://ajrccm.atsjournals.org/cgi/content/short/185/1- MeetingAbstracts/A2913?rss=1 [Accessed 2012 Jun 18]
48. Hass C, Engdahl K, Albert W, et al. Patient preferences and perceived ease of use in inhaler features: Genuair vs other inhalers [abstract]. Chest 2010; 138 (4-MeetingsAbstracts): 484A [online]. Available from URL: http://journal.publica tions.chestnet.org/mobile/article.aspx?articleid=1087181 [Accessed 2012 Jun 18]
49. Almirall, S.A./Forest Laboratories. Long-term efficacy and safety of aclidinium/formoterol fixed-dose combination [ClinicalTrials.gov identifier NCT01462942]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2012 Jul 16]
50. Forest Laboratories/Almirall, S.A. Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28-weeks treatment in patients with moderate to severe, stable chronic obstructive pulmonary disease (COPD) [ClinicalTrials.gov identifier NCT01572792]. US National Institutes of Health, ClinicalTrials. gov [online]. Available from URL: http://clin icaltrials.gov [Accessed 2012 Jul 16]
51. Forest Laboratories/Almirall, S.A. Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC) [ClinicalTrials.gov identifier NCT01437397]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials. gov [Accessed 2012 Jul 16]
52. Forest Laboratories/Almirall, S.A. Safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (LAC) [Clinical-Trials.gov identifier NCT01437540]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2012 Jul 16]